Beijing Med-Pharm Corporation (BJGP.PK) today announced that Fred M. Powell will serve as Chief Financial Officer.
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--April 6, 2005--Beijing Med-Pharm Corporation (BJGP.PK) today announced that Fred M. Powell will serve as Chief Financial Officer.
Mr. Powell comes to Beijing Med-Pharm from EXIMIAS Pharmaceutical Corporation where he served as Chief Financial Officer and completed a $63.5 million private financing in 2004. Mr. Powell also served as Chief Financial Officer at Premier Research Worldwide at the time of their initial public offering.
"We are very pleased to bring on board a top-notch financial executive such as Fred Powell," says Martyn Greenacre, Chairman of Beijing Med-Pharm. "Fred has had considerable experience working with emerging life science companies and with the financial community. He's an excellent fit for our needs."
"I am excited to join the Beijing Med-Pharm team and look forward to helping the company during what I hope to be a time of considerable growth," said Mr. Powell. Mr. Powell joins Beijing Med-Pharm with more than 20 years of public accounting and corporate finance experience.
From 2002-2004, he served as Chief Financial Officer of EXIMIAS Pharmaceutical Corporation, a pharmaceutical company that develops novel oncology products.
Mr. Powell worked at InnaPhase Corporation from 1999-2002 as Senior Vice President, Finance and Administration. During his tenure, InnaPhase completed two private financings as well as an acquisition of a pharmaceutical software business.
Mr. Powell served from 1993-1999 at Premier Research Worldwide, a leading contract research organization to the pharmaceutical industry. As Chief Financial Officer, Mr. Powell helped Premier complete its initial public offering and several acquisitions including that of DLB, a clinical trial and data management software company.
Mr. Powell spent six years at KPMG Peat Marwick as a senior manager responsible for directing the planning, coordination and delivery of audit management and technology services to clients in the pharmaceutical and services industries.
Mr. Powell graduated from Penn State University with a Bachelor of Science in Accounting and is a Certified Public Accountant.
About Beijing Med-Pharm
Beijing Med-Pharm Corporation (www.beijingmedpharm.com) is a Delaware corporation with subsidiary pharmaceutical marketing operations in China. Beijing Med-Pharm's services include pre-market entry analysis; market research; clinical trial management; product registration; and pharmaceutical marketing to physicians, hospitals, and other healthcare providers. For more information, contact Ben Austin at 917-686-3979 or baustin@beijingmedpharm.com .
# # #
Beijing Med-Pharm Corp. has filed a registration statement with the Securities and Exchange Commission relating to the sale of its common stock. This registration statement has not yet become effective. The securities covered by the registration statement may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.